Dr Orlowski
Badros AZ et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood 2024:[Online ahead of print]. Abstract
Facon T et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;391(17):1597-609. Abstract
Leleu X et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: The randomized phase 3 BENEFIT trial. Nat Med 2024;30(8):2235-41. Abstract
Moreau P et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: Long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol 2024;25(8):1003-14. Abstract
Sonneveld P et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390(4):301-13. Abstract
Usmani SZ et al. Daratumumab + bortezomib/lenalidomide/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: Results of the phase 3 CEPHEUS study. IMS 2024;Abstract OA-63.
Dr Richardson
Attal M et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet 2019;394(10214):2096-107. Abstract
Auner HW et al. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Am J Hematol 2021;96(6):708-18. Abstract
Bahlis NJ et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood 2018;132(24):2546-54. Abstract
Baljevic M et al. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. EJHaem 2022;3(4):1270-6. Abstract
Bobin A et al. Multicenter open label phase 2 study of quadruplet-based regimen iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in early relapsed or refractory multiple myeloma - IFM2018-03. Blood 2023;142(Suppl 1):6742;Abstract 6742.
Capra M et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. Haematologica 2022;107(6):1397-409. Abstract
Chari A et al. Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381(8):727-38. Abstract
Chen C et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood 2018;131(8):855-63. Abstract
Dhakal B et al. Dual targeting of slamf-7 and CD38 in multiple myeloma (MM): A phase II study of isatuximab, elotuzumab, pomalidomide and dexamethasone (isa-elopd) in relapsed and/or refractory MM (RRMM). Blood 2023;142(Suppl 1):3379-80;Abstract 3379.
Dimopoulos MA et al. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am J Hematol 2023;98(1):E15-19. Abstract
Dimopoulos MA et al. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia 2021;35(2):562-72. Abstract
Facon T et al. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study. Hematol Oncol 2024;42(2):e3258. Abstract
Facon T et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol 2022;40(5):1020-9. Abstract
Gasparetto C et al. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. Br J Cancer 2022;126(5):718-25. Abstract
Gasparetto C et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. EJHaem 2021;2(1):56-65. Abstract
González-Calle V et al. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: Results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study. Haematologica 2024;109(7):2219-28. Abstract
Grosicki S et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet 2020;396(10262):1563-73. Abstract
Harrison SJ et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol 2021;194(1):120-31. Abstract
Kawano Y et al. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: Updated IKEMA subgroup analysis. Clin Lymphoma Myeloma Leuk 2023;23(10):e360-7. Abstract
Martin T et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J 2023;13(1):72. Abstract
Martin T et al. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Adv 2022;6(15):4506-15. Abstract
Martin TG et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma: IKEMA subgroup analysis by prior transplantation. Transplant Cell Ther 2023;29(2):134.e1-7. Abstract
Mateos MV et al. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. J Hematol Oncol 2021;14(1):59. Abstract
Midha S et al. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. Expert Opin Drug Saf 2023;22(11):1049-71. Abstract
Mo CC et al. Selinexor: Targeting a novel pathway in multiple myeloma. EJHaem 2023;4(3):792-810. Abstract
Moreau P et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial. Lancet 2021;397(10292):2361-71. Abstract
Nooka AK et al. Guidance for use and dosing of selinexor in multiple myeloma in 2021: Consensus from international myeloma foundation expert roundtable. Clin Lymphoma Myeloma Leuk 2022;22(7):e526-31. Abstract
Qiu L et al. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): A phase II, single-arm study. BMC Med 2022;20(1):108. Abstract
Quach H et al. A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica 2024;[Online ahead of print]. Abstract
Richard S et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol 2021;96(9):1120-30. Abstract
Richardson PG et al. Isatuximab-pomalidomide-dexamethasone versuspomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: Final overall survival analysis. Haematologica 2024;109(7):2239-49. Abstract
Richardson PG et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study. Lancet Oncol 2022;23(3):416-27. Abstract
Richter J et al. Updated results from a matching-adjusted indirect comparison of efficacy outcomes of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood 2023;142(suppl 1):6734. Abstract
Schiller GJ et al. Selinexor-based triplet regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies. Clin Lymphoma Myeloma Leuk 2023;23(9):e286-96. Abstract
Schjesvold FH et al. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica 2021;106(4):1182-7. Abstract
Schjesvold FH et al. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Am J Hematol 2021;96(11):E423-7. Abstract
Sunami K et al. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Clin Lymphoma Myeloma Leuk 2022;22(8):e751-61. Abstract
Vogl DT et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 2018;36(9):859-66. Abstract
White D et al. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Front Oncol 2024;14:1352281. Abstract
White D et al. Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). J Clin Oncol 2021;13(15_suppl):8018. Abstract
Yong K et al. Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): Overall survival analysis of a phase 3, randomised, controlled trial. Lancet Haematol 2024;11(10):e741-50. Abstract
Yong K et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): Final overall survival analysis. IMS 2023;Abstract OA-48.
Dr Raje
Bal S et al. BMS-986393 (CC-95266), a G protein–coupled receptor class C group 5 member D (GPRC5D)–targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Updated results from a phase 1 study. ASH 2023;Abstract 219.
Berdeja JG et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. Lancet 2021;398(10297):314-24. Abstract
Cohen AD et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 2023;141(3):219-30. Abstract
Cohen AD et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 2022;12:32. Abstract
Dima D et al. Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma. ASH 2023;Abstract 91.
Ferreri CJ et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J 2023;13:117. Abstract 766
Ghilardi G et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Medicine 2024;30:984-9. Abstract
Lesokhin AM et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259-67. Abstract
Mateos M-V et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (soc) in lenalidomide (len)-refractory multiple myeloma (MM): Phase 3 CARTITUDE-4 study update. IMS 2024;Abstract OA-65.
Moreau P et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387(6):495-505. Abstract
Munshi NC et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705-16. Abstract
Nooka AK et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. ASCO 2023;Abstract 8008.
Rodriguez-Otero P et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388:1002-14. Abstract
San-Miguel J et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389:335-47. Abstract
Dr Moreau
Bahlis NJ et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: Results from cohort a of the magnetismm-3 study. Blood 2022;140(S1):391-3. Abstract
Chari A et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Phase 1/2 results from MonumenTAL-1. ASH 2022;Abstract 157.
Cohen YC et al. Talquetamab (tal) + teclistamab (tec) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results from RedirecTT-1 with >1 year of follow-up. IMS 2024;Abstract OA-03.
Garfall AL et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. ASCO 2024;Abstract 7540.
Leshokin AM et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259-67. Abstract
Nooka AK et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. ASCO 2022;Abstract 8007.
Piron B et al. Quad-class exposed/refractory myeloma is associated with short survival. BJHaem 2023;204(1):186-90. Abstract
Schinke CD et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8036.
Tomasson M et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM). ASH 2023;Abstract 3385.
Touzeau C et al. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood 2024;144(23):2375-88. Abstract
Dr Lonial
Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 2024;391(5):408-21. Abstract
Farooq AV et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody–drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther 2020;9:889-911. Abstract
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2024;391(5):393-407. Abstract
Kaufman JL et al. First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib - dexamethasone vs carfilzomib - dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma. IMS 2023;Abstract OA-29.
Kaufman JL et al. Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma. IMS 2023;Abstract P-277.
Lonial S et al. Iberdomide (iber) in combination with dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM): Results from the anti-B-cell maturation antigen (BCMA)-exposed cohort of the CC-220-MM-001 trial. Blood 2022;140(S1):4398-400. Abstract
Lonial S et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J 2021;11:103. Abstract
Lonial S et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21(2):207-21. Abstract
Lonial S et al. Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). ASCO 2020;Abstract 8536.
Lonial S et al. Recovery of ocular events with longer-term follow-up in the DREAMMM-2 study of single-agent belantamab mafodotin (belamaf) in patients with relapsed or refractory multiple myeloma (RRMM). ASH 2020;Abstract 3224.
Mateos M-V et al. Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM). ASCO Plenary Series 2024;Abstract 439572.
Richardson PG et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial. ASH 2023;Abstract 1013.
Trudel S et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). ASCO 2024;Abstract LBA105.